The utilisation and expenditure of medicines for the prophylaxis and treatment of osteoporosis

Irish Medical Journal

Volumn 101, Issue 2, 2008, Pages

  McGowan, B ^a   Bennett, K ^a   Barry, M ^a   Canny, M ^b  

^a ST JAMES S HOSPITAL   (Ireland)

^b HEALTH SERVICE EXECUTIVE   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALENDRONIC ACID PLUS COLECALCIFEROL; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CORTICOSTEROID; ETIDRONIC ACID; IBANDRONIC ACID; PREDNISOLONE; PROTON PUMP INHIBITOR; RALOXIFENE; RISEDRONIC ACID; STEROID; STRONTIUM RANELATE; TIBOLONE;

AGED; ARTICLE; CONTROLLED STUDY; DATA BASE; DRUG COST; DRUG SUBSTITUTION; DRUG UTILIZATION; DRUG WITHDRAWAL; HUMAN; IRELAND; LONG TERM CARE; MAJOR CLINICAL STUDY; OSTEOPOROSIS; PRESCRIPTION; PUBLIC HEALTH SERVICE; REIMBURSEMENT; CLINICAL PRACTICE; ECONOMICS; PILOT STUDY; STATISTICS;

ADRENAL CORTEX HORMONES; DIPHOSPHONATES; DRUG COSTS; DRUG UTILIZATION; HUMANS; IRELAND; OSTEOPOROSIS; PHYSICIAN'S PRACTICE PATTERNS; PILOT PROJECTS; PRESCRIPTIONS, DRUG; PROTON PUMP INHIBITORS;

EID: 45549094629     PISSN: 03323102     EISSN: 03323102     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002;359:1761-7.
2. BNF. Drugs affecting bone metabolism. British National Formulary 2006:386-7.
3. Van Staa TP, Dennison EM, Leufkens HE, Cooper C. Epidemiology of fractures in England and Wales. Bone 2001;29:557-67.
4. Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 2004;35:375-82.
5. Cranney A Guyatt G, Griffith L, et al. Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002;23:570-8.
6. American College of Rheumatology ad hoc committee on glucocorticoid- induced osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. 2001 Update. Arthritis Rheumatology 2001;44:1496-503.
7. Hougardy DM, Peterson GM, Bleasel MD, Randall CT. Is enough attention being given to the adverse effects of corticosteroid therapy? J Clin Pharm Ther 2000;25:227-34.
8. Van Staa TP, Leufkens HG, Abenhaim L, Begaud B, Zhang B, Cooper C. Use of oral corticosteroids in the United Kingdom. QJM 2000;93:105-11.
9. Yeap SS, Hosking DJ. Management of corticosteroid-induced osteoporosis. Rheumatology 2002;41:1088-94.
10. Feely J, Chan R, McManus J, O'Shea B. The influence of hospitalbased prescribers on prescribing in General Practice. Pharmacoeconomics 1999;16:175-81.
11. Health Service Executive. National Shared Services Primary Care Reimbursement Service, Statistical Analysis of Claims and Payments. 2002-2005.
12. Schnitzer T, Bone HG, Crepaldi G, al. e. Therapeutic equivalence of alendronate 70mg once-weekly and alendronate 10mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 2000;12:1-12.
13. The Alendronate Once-weekly Study Group. Two-year results of onceweekly administration of alendronate 70mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 2002;17:1988-96.
14. Hosking D, Adami S, Felsenberg D, et al. Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study. Current Medical Research and Opinion 2003;vol 19:383-94.
15. Rossen CJ, Hochberg MC, Bonnick SL, et al. Treatment With Once- Weekly Alendronate 70mg Compared With Once-Weekly Risedronate 35mg in Women With Postmenopausal Osteoporosis: A Randomized Bouble-Blind Study. Journal of Bone and Mineral Research 2005;20(1).
16. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term Proton Pump Inhibitor Therapy and Risk of Hip Fracture. Jama 2006;296:2947-53.
17. Eastell R, Reid DM, Compston J, et al. A UK Consensus Group on management of glucorticoid-induced osteoporosis: an update. Journal of Internal Medicine 1998;244:271-92.
18. Leong GM, Center JR, Henderson NK, Eisman JA. Glucocorticoidinduced osteoporosis. In: Marcus R, Feldman D, Kelsey J (eds). Osteoporosis 2001;2:69-93.
19. Blake GM, Fogelman L. Bone densitometry, steroids and osteoporosis. Current Opin Nephrol Hypertension 2002;11:641-7.
20. Cooper C, Coupland C, Mitchell M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis 1995;54:49-52.
21. Scane AC, Francis RM, Sutcliffe AM, Francis MJ, Rawlings DJ, Chapple CL. Case-control study of the pathogenesis and sequelae of symptomatic vertebral fractures in men. Osteoporosis Int 1999;9:91-7.
22. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990;112:325-64.
23. Kanis JA, Pitt FA. Epidemiology of osteoporosis. Bone 1992;13(Suppl 1):S7-15.